CA2306790A1 - Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques - Google Patents

Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques Download PDF

Info

Publication number
CA2306790A1
CA2306790A1 CA002306790A CA2306790A CA2306790A1 CA 2306790 A1 CA2306790 A1 CA 2306790A1 CA 002306790 A CA002306790 A CA 002306790A CA 2306790 A CA2306790 A CA 2306790A CA 2306790 A1 CA2306790 A1 CA 2306790A1
Authority
CA
Canada
Prior art keywords
tnf
serum level
interleukin
antagonists
tnf antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306790A
Other languages
English (en)
Inventor
Hartmut Kupper
Martin Kaul
Jurgen Eiselstein
Lothar Daum
Joachim Kempeni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306790A1 publication Critical patent/CA2306790A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Utilisation d'antagonistes du TNF pour la préparation de médicaments destinés à traiter les maladies septiques caractérisées par une augmentation du taux sérique d'interleukine-6 pendant un intervalle de mesure d'au moins trente minutes.
CA002306790A 1997-10-23 1998-10-15 Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques Abandoned CA2306790A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19746868.3 1997-10-23
DE19746868A DE19746868A1 (de) 1997-10-23 1997-10-23 Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
PCT/EP1998/006545 WO1999021582A2 (fr) 1997-10-23 1998-10-15 Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques

Publications (1)

Publication Number Publication Date
CA2306790A1 true CA2306790A1 (fr) 1999-05-06

Family

ID=7846420

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306790A Abandoned CA2306790A1 (fr) 1997-10-23 1998-10-15 Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques

Country Status (13)

Country Link
EP (1) EP1024831A2 (fr)
JP (1) JP2001521009A (fr)
KR (1) KR20010024549A (fr)
CN (1) CN1163272C (fr)
AU (1) AU756167B2 (fr)
BR (1) BR9813114A (fr)
CA (1) CA2306790A1 (fr)
DE (1) DE19746868A1 (fr)
HU (1) HUP0100105A3 (fr)
IL (1) IL135083A0 (fr)
NO (1) NO20001894L (fr)
WO (1) WO1999021582A2 (fr)
ZA (1) ZA989615B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
JP2013532181A (ja) 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び胃腸管の機能的な疾患又は状態を治療する方法
ES2398646T3 (es) * 2010-07-24 2013-03-20 F. Hoffmann-La Roche Ag Estabilización de la interleuquina-6 en soluciones de suero

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

Also Published As

Publication number Publication date
AU1228499A (en) 1999-05-17
IL135083A0 (en) 2001-05-20
DE19746868A1 (de) 1999-04-29
KR20010024549A (ko) 2001-03-26
HUP0100105A2 (hu) 2001-05-28
JP2001521009A (ja) 2001-11-06
WO1999021582A2 (fr) 1999-05-06
NO20001894D0 (no) 2000-04-12
CN1277556A (zh) 2000-12-20
EP1024831A2 (fr) 2000-08-09
BR9813114A (pt) 2000-08-15
NO20001894L (no) 2000-04-12
AU756167B2 (en) 2003-01-09
HUP0100105A3 (en) 2003-08-28
WO1999021582A3 (fr) 1999-07-15
CN1163272C (zh) 2004-08-25
ZA989615B (en) 2000-04-20

Similar Documents

Publication Publication Date Title
US6235281B1 (en) Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
US20030012786A1 (en) Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
EP0966300B1 (fr) Traitement de la polyarthrite rhumatoide avec un anticorps anti ifn gamma
US20030161828A1 (en) Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
EP0783893B1 (fr) Inhibition de la croissance anormale de cellules synoviales a l' aide d' un antagoniste d'interleukine 6 comme principe actif
US20090148446A1 (en) Method and Composition for Treatment of Renal Failure with Antibodies and Their Equivalents as Partial or Complete Replacement for Dialysis
RU2607022C2 (ru) Способы и композиции для лечения волчанки
CN105705518A (zh) 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
JP2015013887A (ja) アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法
CN1946734B (zh) 系统性治疗关节炎的组合物和方法
AU756167B2 (en) Application of TNF antagonists as medicaments for treating septic diseases
KR20020027493A (ko) 종양 전이를 저해하는 인터루킨-18 저해물질의 용도
JP2003531822A (ja) 自己免疫疾患を治療するためのｔｈ−１免疫反応誘導サイトカインの拮抗薬
KR100414505B1 (ko) 높은혈청수준의인터류킨-6을갖는질환을치료하기위한약물로서의항-tnf항체의용도
MXPA00003355A (en) Application of tnf antagonists as medicaments for treating septic diseases
AU5394001A (en) The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
CZ20001407A3 (cs) Použití TNF antagonistů pro výrobu drog k léčení septických poruch
AU1549599A (en) The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of the interleukin-6
WO2026094824A1 (fr) Utilisation d'un inhibiteur de pad pour le traitement ou la prévention de l'arthrite auto-immune
AU732764B2 (en) Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
HK1135027A (en) Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
HK1127497B (en) Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued